Lynkuet Bayer AG · Authorised · authorised 17 Nov 2025 · ATC G02CX07
Therapeutic indication (EMA)
Treatment of moderate to severe vasomotor symptoms (VMS).
Active substance
Elinzanetant
- US FDA 1
- EMA 1
- Health Canada 1
- US price lines 1
US FDA United States — FDA approvals (Drugs@FDA)
| Product | Strength | Form · route | Applicant | Status | First approved |
|---|---|---|---|---|---|
| LYNKUET | 60MG | capsule · oral | BAYER HLTHCARE | Prescription | 24 Oct 2025 |
EMA European Union — centrally authorised medicines
Canada Canada — marketed products (Health Canada)
| Brand | DIN | Strength | Form · route | Company |
|---|---|---|---|---|
| LYNKUET | 02559714 | 60 MG | CAPSULE · ORAL | BAYER INC |
Prices — United States and England
| Source | Product as listed | Price | Unit / pack | Date |
|---|---|---|---|---|
| US NADAC | LYNKUET 60 MG CAPSULE | $9.97051 | per EA | 30 Sep 2026 |
NADAC: average price US retail pharmacies pay to buy the medicine. NHS Drug Tariff Part VIIIA: basic price reimbursed to pharmacies in England and Wales.
Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.